Main Research Areas (Recruitment Fields) and Content
Biology
1. Cell Biology
Research on the relationship between inflammation, metabolism, non-coding RNA, immunity, viruses, and hepatobiliary tumors
Clinical Medicine
1. Surgery
Diagnosis and treatment of common and frequently occurring diseases in general surgery
Research on the mechanisms of occurrence, metastasis, recurrence, and drug resistance reversal in hepatobiliary tumors
Studies on minimally invasive, comprehensive, and immunotherapy treatments for hepatobiliary tumors, as well as organ transplantation
Born in October 1970, Professor, Chief Physician, PhD Supervisor, and Postdoctoral Mentor. Currently serving as the Party Secretary of the School of Life Sciences and Medicine at the University of Science and Technology of China and the Party Secretary of the First Affiliated Hospital. Graduated in 2000 from Harbin Medical University with a PhD in Surgery. Chief Scientist of the Ministry of Science and Technology's Transformative Technology major project, leader of the Ministry of Education's Innovation Team Development Plan, and a leading talent in science and technology innovation for young and middle-aged scientists by the Ministry of Science and Technology. Recipient of the State Council's Special Government Allowance, National Famous Doctor • Excellent Role Model, Heilongjiang Provincial Model Worker, and the first Longjiang Famous Doctor awards. Has undertaken and led six National Natural Science Foundation projects, three national key R&D plans by the Ministry of Science and Technology, the Ministry of Education's Innovation Team Development Plan, the Ministry of Education's New Century Excellent Talents Support Program, Heilongjiang Provincial Natural Science Foundation, Heilongjiang Provincial Outstanding Youth Fund, and the Heilongjiang Provincial University Science and Technology Innovation Team Support Plan. Published nearly 200 professional academic papers as the first and corresponding author, with over 80 papers indexed by SCI, including one with an impact factor over 20 and more than ten with an impact factor over 10. Research findings published in prestigious journals like Hepatology, PNAS, Nature Communications, Gut, and Journal of Hepatology, with a highest single paper impact factor of 20.582.
Education and Work Experience
- 1988.09–1993.07: Harbin Medical University, Clinical Medicine, Bachelor's
- 1995.09–1997.07: Harbin Medical University, General Surgery, Master's
- 1997.09–2000.07: Harbin Medical University, General Surgery, PhD
- 2000.11–2003.03: Chinese Academy of Medical Sciences & Peking Union Medical College, Postdoctoral
- 2001.07–2001.08: Nagoya University, Hamamatsu University School of Medicine, Aichi Cancer Center Hospital, Japan, Visiting Scholar
- 2002.01–2002.08: St. George Hospital, University of New South Wales, Sydney, Australia, Visiting Scholar
- 2000.07–2001.10: Harbin Medical University, First Affiliated Hospital, Lecturer
- 2001.11–2003.08: Harbin Medical University, First Affiliated Hospital, Associate Professor, Associate Chief Physician
- 2003.09–2018.10: Harbin Medical University, First Affiliated Hospital, Professor, Chief Physician
- 2018.11–Present: University of Science and Technology of China, First Affiliated Hospital, Professor, Chief Physician
Academic Achievements and Impact
For over 20 years, dedicated to teaching general surgery and clinical research on hepatobiliary and pancreatic tumors. Main research interests include the mechanisms of occurrence, development, and metastasis of hepatobiliary and pancreatic tumors, focusing on the relationships between inflammation, metabolism, non-coding RNA, immunity, viruses, and these tumors. Awarded the Ministry of Education's First Prize in Natural Science, First Prize in Scientific and Technological Progress, Second Prize in Scientific and Technological Progress, Heilongjiang Provincial First Prize in Natural Science, Second Prize in Scientific and Technological Progress, Third Prize in Scientific and Technological Progress, First Prize in Medical and Health Science and Technology Progress, First Prize in Medical New Technology, Second Prize, and Third Prize.
Published over 200 professional academic papers as the first and corresponding author, with more than 80 papers indexed by SCI, including one with an impact factor over 20 and more than ten with an impact factor over 10. Research findings published in prestigious journals like Hepatology, PNAS, Nature Communications, Gut, and Journal of Hepatology, with a highest single paper impact factor of 20.582. Chief editor of one monograph, associate editor of two, and contributor to 13 (including two in English).
Ongoing Projects (Principal Investigator Only)
1. Project Name, Source, Funding ID: Precision Capture and High-Resolution Single-Molecule Analysis of Single Cells in Hepatobiliary and Pancreatic Tumors, National Key R&D Program; Total Funding (10,000 RMB): 2115; Duration: June 2020 to May 2025
2. Project Name, Source, Funding ID: Role of Long Non-Coding RNA-Mediated Amino Acid and Lipid Metabolism Reprogramming in Hepatocarcinogenesis, National Natural Science Foundation Joint Fund; Total Funding (10,000 RMB): 247; Duration: January 2020 to December 2023
3. Project Name, Source, Funding ID: Mechanistic Study of the lncRNA HMMR-AS1/miR-188-3p/NCAPG2 Pathway in Hepatocellular Carcinoma, National Natural Science Foundation General Project; Total Funding (10,000 RMB): 55; Duration: January 2020 to December 2023
4. Project Name, Source, Funding ID: Application of Transplantation Technology in End-Stage Liver Disease and Hematological Malignancies, Anhui Provincial University Collaborative Innovation Project; Total Funding (10,000 RMB): 200; Duration: July 2019 to June 2022
5. Project Name, Source, Funding ID: Role of Long Non-Coding RNA-XIST in Amino Acid Metabolism Reprogramming Related to Liver Cancer Metastasis, National Natural Science Foundation General Project; Total Funding (10,000 RMB): 52; Duration: January 2018 to December 2021
Representative Papers (Last Five Years)
Zhang B, Meng F, Liu Y, Yuan Y, Wang J, Wu D, Cui Y, Zhang S, Guo H, Liang S, Wang W, Klos M, Morgenstern S, Liu Y, Sun L, Ma K, Liu X, Wang Y, Han J, Yang G, Zheng C, Li X, Zhou S, Ji C, Bai Q, Wang J*, Liu L*. Inhibition of TGFβ1 accelerates regeneration of fibrotic rat liver elicited by a novel two-staged hepatectomy. Theranostics. 2021;11(10):4743-4758. （corresponding author）
Pei Tiemin#, Meng Fanzheng#, Xiao Peng, Han Jihua, Song Ruipeng, Lan Yaliang, Wang Yan , Xue Junlin, Lang Qingfu, He Zhefeng, Li Jian, Guo Zihao, Liu Guoxing, Sun Boshi, Zhao Ming, Meng Qinghui*, Liang Desen*, Liu Lianxin*. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways. Journal of Hepatology. 2020 Apr; 72(4): 761-773.（corresponding author）
Dehai Wu#, Yan Wang#, Guangchao Yang#, Shugeng Zhang#, Yao Liu#, Shuo Zhou, Hongrui Guo, Shuhang Liang, Yifeng Cui, Bo Zhang, Kun Ma, Congyi Zhang, Yufeng Liu, Linmao Sun, Jiabei Wang*, Lianxin Liu*. A novel mitochondrial amidoxime reducing component 2 is a favorable indicator of cancer and suppresses the progression of hepatocellular carcinoma by regulating the expression of p27. Oncogene. 2020 Sep;39(38):6099-6112.（corresponding author）
Yao Liu#, Fanzheng Meng#, Jiabei Wang#, Mingyang Liu#, Guangchao Yang#, Ruipeng Song, Tongsen Zheng, Yingjian Liang, Shugeng Zhang, Dalong Yin, Jizhou Wang, Haiyan Yang, Shangha Pan, Bo Sun, Jihua Han, Jing Sun, Yaliang Lan, Yan Wang, Xirui Liu, Mingxi Zhu, Yifeng Cui, Bo Zhang, Dehai Wu, Shuhang Liang, Yufeng Liu, Xuan Song, Zhaoyang Lu, Jingxuan Yang, Min Li*, Lianxin Liu*. A Novel Oxoglutarate Dehydrogenase-Like Mediated miR-214/TWIST1 Negative Feedback Loop Inhibits Pancreatic Cancer Growth and Metastasis. Clinical Cancer Research. 2019 Sep 1; 25(17): 5407-5421.（corresponding author）
Wang, Jiabei#; Xie, Changming#; Pan, Shangha#; Liang, Yingjian#; Han, Jihua#; Lan, Yaliang; Sun, Jing; Li, Keyu; Sun, Boshi; Yang, Guangchao; Shi, Huawen; Li, Yuejin; Song, Ruipeng; Liu, Xirui; Zhu, Mingxi; Yin, Dalong; Wang, Huanlai; Song, Xuan; Lu, Zhaoyang; Jiang, Hongchi; Zheng, Tongsen*; Liu, Lianxin*, N-myc downstream-regulated gene 2 inhibits human cholangiocarcinoma progression and is regulated by leukemia inhibitory factor/MicroRNA-181c negative feedback pathway. Hepatology, 2016.11, 64(5): 1606~1622.（corresponding author）
Hong, Xuehui#; Liu, Wenyu#; Song, Ruipeng; Shah, Jamie J.; Feng, Xing; Tsang, Chi Kwan; Morgan, Katherine M.; Bunting, Samuel F.; Inuzuka, Hiroyuki; Zheng, X. F. Steven; Shen, Zhiyuan; Sabaawy, Hatem E.; Liu, LianXin* ; Pine, Sharon R* , SOX9 is targeted for proteasomal degradation by the E3 ligase FBW7 in response to DNA damage, Nucleic Acids Research, 2016.10.14, 44(18): 8855~8869.（corresponding author）
Contact Information
E-mail: liulx@ustc.edu.cn
Phone: 0551-62284121